Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2012
Event Date: May 8, 2012
Context: The Company disclosed the award of a government research and development grant to its wholly owned Israeli subsidiary, Oramed Ltd.
Key Financial Metrics
Grant Amount: NIS 2 million (approximately $540,000 USD).
Grant Period: December 2011 to November 2012.
Grantor: Office of the Chief Scientist (OCS), Ministry of Industry, Trade and Labor of Israel.
Revenue/Profit/Cash Flow: The filing text does not provide a clear value for current revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses solely on the grant award.
Material Changes and Obligations
- Royalty Obligation: Oramed Ltd. is required to pay royalties at a rate of 3% to 5% on sales of products and services derived from technology developed using this grant (and other OCS grants).
- Repayment Condition: Royalties are payable until 100% of the dollar-linked grant amount plus interest is repaid.
- Contingency: In the absence of such sales, no royalty payment is required.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release confirming the grant award as government participation in R&D expenses.
Risks/Contingencies: Future financial obligations are contingent upon the commercial success of products derived from the funded technology. If no sales occur, the royalty obligation does not trigger.
Outlook: The filing does not provide specific financial guidance or future earnings projections beyond the grant terms.
Investor Verification Checklist
- Verify the exact exchange rate used to convert NIS 2 million to approximately $540,000 USD.
- Confirm the specific R&D projects covered under the December 2011 to November 2012 grant period.
- Review the full text of the attached press release (Exhibit 99.1) for additional details on the grant's impact on the balance sheet.
- Assess the potential future liability of the 3%-5% royalty rate based on projected sales of related products.